The value of 11C-methionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a high-grade glioma and indeterminate MRI

被引:12
作者
Garcia, J. R. [1 ]
Cozar, M. [1 ]
Baquero, M. [1 ]
Fernandez Barrionuevo, J. M. [1 ]
Jaramillo, A. [1 ]
Rubio, J. [1 ]
Maida, G. [1 ]
Soler, M. [1 ]
Riera, E. [1 ]
机构
[1] CETIR ERESA, CETIR Unidad PET, Barcelona, Spain
来源
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR | 2017年 / 36卷 / 02期
关键词
C-11-Methionine PET; Glioma; Tumour recurrence; Radionecrosis; MRI; POSITRON-EMISSION-TOMOGRAPHY; RADIATION NECROSIS; BRAIN-TUMORS; DIAGNOSTIC-ACCURACY; METHIONINE; F-18-FDG; FLUORODEOXYGLUCOSE;
D O I
10.1016/j.remn.2016.06.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To evaluate the contribution of(11)C-Methionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a high grade glioma. Method: The study included-30 patients with glioma (III/IV grade) treated with surgery/radiotherapy/ chemotherapy (5-8 months) and with an indeterminate MRI. All patients underwent a C-11-Methione PET (within 15 days of MRI) and studies were visually analysed (intensity and morphology of uptake), quantified (SUV max/SUV mean background), and coregistered to MRI (3D-Flair). Patient management was decided by the neuro-oncology committee to clinical and imaging follow-up, second-line treatment, or surgery. Results: There were 23 C-11-Methionine PET studies visually positive. Morphology of uptake was focal in 15, diffuse in 4, and ring-shaped in 4. Three out of the focal uptake cases underwent resection (Histopathology +). Sixteen underwent second line therapy (11 responded; 5 progressed). The 4 cases with ring-shaped uptake were followed-up, and progression was found in 2 (true-positive), and disease-free in 2 (follow-up of 6 and 7 months, respectively) (false-positive). Seven out of(11)C-Methionine studies PET were visually negative, and all of them were disease-free (followup of 3-12 months). SUV lesion/background was 2.79 +/- 1.35 in tumour recurrence, and 1.53 +/- 0.39 in radionecrosis (P <.05). Taking into account a SUV lesion/background threshold of 2.35, the sensitivity and specificity values were 90.5% and 100%, respectively. Conclusion: Visual analysis, quantitative and PET/MRI coregistration of C-11-Methionine PET showed their complementary role in patients with indeterminate MRI results, thus allowing early differentiation between tumour recurrence and radionecrosis, and helping in the individual therapy approach. (C) 2016 Elsevier Espana, S.L.U. y SEMNIM. All rights reserved.
引用
收藏
页码:85 / 90
页数:6
相关论文
共 26 条
[1]   Neuroimaging in brain tumors [J].
Arbizu, J. ;
Dominguez, P. D. ;
Diez-Valle, R. ;
Vigil, C. ;
Garcia-Eulate, R. ;
Zubieta, J. L. ;
Richter, J. A. .
REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2011, 30 (01) :47-65
[2]  
Ceyssens S, 2006, AM J NEURORADIOL, V27, P1432
[3]   Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET [J].
Chung, JK ;
Kim, YK ;
Kim, SK ;
Lee, YJ ;
Paek, S ;
Yeo, JS ;
Jeong, JM ;
Lee, DS ;
Jung, HW ;
Lee, MC .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (02) :176-182
[4]   11C-MET PET/CT and Advanced MRI in the Evaluation of Tumor Recurrence in High-Grade Gliomas [J].
D'Souza, Maria M. ;
Sharma, Rajnish ;
Jaimini, Abhinav ;
Panwar, Puja ;
Saw, Sanjiv ;
Kaur, Prabhjot ;
Mondal, Anupam ;
Mishra, Anil ;
Tripathi, Rajendra P. .
CLINICAL NUCLEAR MEDICINE, 2014, 39 (09) :791-798
[5]   Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: Preliminary results in clinical practice [J].
Dandois, V. ;
Rommel, D. ;
Renard, L. ;
Jamart, J. ;
Cosnard, G. .
JOURNAL OF NEURORADIOLOGY, 2010, 37 (02) :89-97
[6]   11C-Methionine Positron Emission Tomographic Imaging of Biologic Activity of a Recurrent Glioblastoma Treated with Stereotaxy-Guided Laser-Induced Interstitial Thermotherapy [J].
Galldiks, Norbert ;
von Tempelhoff, Wernholt ;
Kahraman, Deniz ;
Kracht, Lutz W. ;
Vollmar, Stefan ;
Fink, Gereon R. ;
Schroeter, Michael ;
Goldbrunner, Roland ;
Schmidt, Matthias ;
Maarouf, Mohammad .
MOLECULAR IMAGING, 2012, 11 (04) :265-271
[7]   Value of 11C-methionine PET in imaging brain tumours and metastases [J].
Glaudemans, Andor W. J. M. ;
Enting, Roelien H. ;
Heesters, Mart A. A. M. ;
Dierckx, Rudi A. J. O. ;
van Rheenen, Ronald W. J. ;
Walenkamp, Annemiek M. E. ;
Slart, Riemer H. J. A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :615-635
[8]   AN INTERINDIVIDUAL COMPARISON OF O-(2-[18F]FLUOROETHYL)-L-TYROSINE (FET)- AND L-[METHYL-11C]METHIONINE (MET)-PET IN PATIENTS WITH BRAIN GLIOMAS AND METASTASES [J].
Grosu, Anca-Ligia ;
Astner, Sabrina T. ;
Riedel, Eva ;
Nieder, Carsten ;
Wiedenmann, Nicole ;
Heinemann, Felix ;
Schwaiger, Markus ;
Molls, Michael ;
Wester, Hans-Juergen ;
Weber, Wolfgang A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04) :1049-1058
[9]   Amino acid PET and clinical management of glioma patients [J].
Herholz, Karl .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (04) :683-684
[10]   Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI [J].
Kim, Yong Hwy ;
Oh, So Won ;
Lim, You Jung ;
Park, Chul-Kee ;
Lee, Se-Hoon ;
Kang, Keon Wook ;
Jung, Hee-Won ;
Chang, Kee Hyun .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2010, 112 (09) :758-765